Catalent Confirms the Appointment of Two Senior Healthcare Executives to its Board of Directors
Catalent, Inc., has appointed Jack Stahl and Rolf Classon to its Board of Directors.
Mr Jack Stahl was President and CEO of Revlon, Inc. between 2002 and 2006. Previously, he acted as President and Chief Operating Officer of The Coca-Cola Company from 2000 to 2001. Mr Stahl also serves on the Boards of Coty, Inc., Delhaize Group, and the US Board of Advisors of CVC Capital. In addition, Mr Stahl formerly served on the Boards of Schering-Plough Corporation and Dr Pepper Snapple Group. He holds a Bachelor’s degree in Economics from Emory University and a Master’s degree from the Wharton School of Business at the University of Pennsylvania.
Mr Rolf Classon was Chairman of the Executive Committee at Bayer HealthCare AG, a subsidiary of Bayer AG, from October 2002 until his retirement in July 2004. He served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President from 1991 to 1995. Prior to 1991, Mr Classon held various management positions with Pharmacia Corporation. Mr Classon currently serves as Chairman of the Boards of Auxilium Pharmaceuticals, Inc., Hill-Rom Corporation, and Tecan Group Ltd, and he serves on the Board of Fresenius Medical Care. Mr Classon served as Vice Chairman of Auxilium Pharmaceuticals, Inc. from March 2005 to April 2005, and he was interim CEO of Hill-Rom Corporation from May 2005 until March 2006. Mr. Classon also served as a Director on the Boards of Millipore Corporation, Prometheus Laboratories Inc., and Enzon Pharmaceuticals, Inc. Mr. Classon received his Chemical Engineering Certificate from the Gothenburg School of Engineering and a Business degree from the Gothenburg University.
Messrs. Stahl and Classon have also joined Catalent’s Audit Committee, with Mr Stahl serving as Chair.
“We welcome both Jack and Rolf to our Board,” commented John Chiminski, President and CEO, Catalent, Inc. “Both are senior healthcare executives, with a wealth of knowledge and experience within the sector. We will look to draw upon their expertise as we embark on the next, exciting stage of our company’s history.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance